COMPANY:

Pillar Biosci

"Pillar Biosciences said Wednesday that more of its OncoReveal next-generation sequencing panels will be offered by Illumina in an expansion of the companies’ existing partnership...The deal includes the OncoReveal Essential MPN, Myeloid, Multi-Cancer with CNV and Fusion panel, and BRCA1 and BRCA2 plus CNV panel, which will be available as part of validated workflows on the MiSeq i100 sequencer launched last week."

"Pillar Biosciences, Inc. has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling panels for detection of genetic cancer variants, with an initial focus on European markets and the UK...The partnership aims to rapidly identify tumors with clinically actionable genomic alterations via liquid biopsy profiling and intends to support faster diagnostic testing by increasing the local availability of plasma-based tumor profiling at leading clinical laboratories....The work will initially leverage Pillar Biosciences oncoReveal Core LBx, Essential LBx, and Fusion LBx research-use-only (RUO) liquid biopsy kitted NGS panels."

"Pillar Biosciences, Inc...has announced the global launch of oncoReveal™ Nexus, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a rapid, targeted solution for solid and hematological malignancies to help accelerate the delivery of targeted therapy...A team at New York’s Memorial Sloan Kettering Cancer Center (MSK), will be the first to utilize oncoReveal™ Nexus, which will be branded MSK-REACT. MSK has already received NYS DOH approval for clinical implementation of MSK-REACT, enabling a more streamlined NGS workflow to help patients get on the right therapy sooner."

"Pillar Biosciences, Inc., the leader in Decision Medicine, has announced that Molecular Pathology Laboratory Network, Inc., (MPLN) is now the first national molecular reference laboratory to verify and launch oncoReveal CDx. The oncoReveal CDx pan-cancer solid tumor IVD kit has been FDA PMA approved for general tumor profiling for 22 clinically relevant genes across all solid tumors, including CDx claims for KRAS (Erbitux & Vectibix) in colorectal cancer (CRC) and EGFR (TKI Class Approval) in non-small cell lung cancer (NSCLC)."

"Pillar Biosciences, Inc...announced that the U.S. Food and Drug Administration (FDA) has approved the company's Premarket Approval (PMA) supplement application for its oncoReveal CDx pan-cancer solid tumor in vitro diagnostic (IVD). The approval expands the indication of oncoReveal Dx from EGFR & KRAS therapy selection in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) to now include general solid tumor profiling."

"Pillar Biosciences, Inc...announced the company and scientific collaborators will collectively present eleven studies and two corporate workshops at the 2023 Association for Molecular Pathology (AMP) Annual Meeting from November 14 -18, 2023 in Salt Lake City, UT (Booth #619)."

"Beckman Coulter Life Sciences...announces a collaboration agreement with Pillar Biosciences, which develops and distributes IVD & RUO NGS testing solutions based on their proprietary SLIMamp® technology to help localize patient testing and optimize the selection of precision therapies for cancer patients...The application development partnership is initially focused on five commercially-available, solid tumor liquid biopsy and hematology panels from Pillar Biosciences..."

"Pillar Biosciences, Inc...has announced the global launch of oncoReveal™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling. The oncoReveal Core LBx is the latest addition to Pillar Biosciences' portfolio of cancer profiling assays designed to enable localized testing and reduce time to treatment initiation."

"Illumina Inc...and Pillar Biosciences Inc...today announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options....Pillar's targeted assays help oncologists and researchers identify mutations that drive tumor growth."

"Pillar Biosciences, Inc..announced a non-exclusive licensing agreement with Keygene N.V. related to their patent family entitled Combinatorial sequence barcodes for high throughput screening for use in Pillar Biosciences products, kits or services used for research or clinical testing."

"Pillar Biosciences, Inc...announced their receipt of the College of American Pathologists (CAP) Accreditation for its CLIA certified reference lab. As one of the most rigorous laboratory certifications, the CAP Accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards of laboratory quality, accuracy, and consistency."

"Beckman Coulter Life Sciences announced...that it has inked an application development agreement with Pillar Biosciences for next-generation sequencing solutions...Under the agreement, Pillar will develop applications designed for Beckman Coulter's Biomek NGenius System, an automated library preparation platform that includes a reagent input carousel, an integrated thermal cycler, and a labware transport system."

"Pillar Biosciences...announced that its oncoReveal Dx Colon Cancer Assay has received approval from the China National Medical Products Administration (NMPA). The IVD assay is now commercially available in China, the U.S., and Europe as a companion diagnostic (CDx) to identify patients with colorectal cancer whose tumors express wild-type KRAS status and may benefit from treatment with specific targeted therapies."

"Pillar Biosciences...announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Premarket Approval (PMA) supplement application for its Pan-cancer oncoReveal™ CDx. The supplement, if approved, will expand the label/indication of Pillar Bioscience’s oncoReveal™ Dx Lung & Colon Cancer Assay to include actionable targets for eight additional cancer types, bringing the total detectable cancers to ten."

"Pillar Biosciences...announced that its abstract, 'Reducing Pre-analytical Sample QC Failure Rates for Cancer Molecular Genetic Assays with SLIMamp® Technology', has been published online in the Journal of Clinical Oncology, in conjunction with the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting...The study showed that oncoReveal™ Solid Tumor Panel with Pillar Biosciences’ proprietary SLIMamp® technology, was able to generate reliable, interpretable results for almost all of the samples that had failed pre-analytical QC for WES."

"Pillar Biosciences...announced the presentation of clinical validation data for the FDA-PMA1 approved oncoReveal Dx Lung & Colon Cancer Assay, along with three additional posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting...Results demonstrate that oncoReveal Dx detects clinically significant variants (KRAS G12/G13, EGFR L858 and exon 19 deletion, and BRAF V600E) from as low as 10ng of DNA input with LoD between 1.5% and 2.6% (VAF, Variant Allele Frequency)."

"Pillar Biosciences...announced that its NGS laboratory, located in Natick, Massachusetts, has passed the onsite inspection and received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS), as well as the Massachusetts state permit."